Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Yin Yang 1 promotes mTORC2-mediated AKT phosphorylation.

Zhang Q, Wan M, Shi J, Horita DA, Miller LD, Kute TE, Kridel SJ, Kulik G, Sui G.

J Mol Cell Biol. 2016 Jun;8(3):232-43. doi: 10.1093/jmcb/mjw002. Epub 2016 Jan 13.

2.

Understanding key assay parameters that affect measurements of trastuzumab-mediated ADCC against Her2 positive breast cancer cells.

Kute T, Stehle JR Jr, Ornelles D, Walker N, Delbono O, Vaughn JP.

Oncoimmunology. 2012 Sep 1;1(6):810-821.

3.

Yin Yang 1 plays an essential role in breast cancer and negatively regulates p27.

Wan M, Huang W, Kute TE, Miller LD, Zhang Q, Hatcher H, Wang J, Stovall DB, Russell GB, Cao PD, Deng Z, Wang W, Zhang Q, Lei M, Torti SV, Akman SA, Sui G.

Am J Pathol. 2012 May;180(5):2120-33. doi: 10.1016/j.ajpath.2012.01.037. Epub 2012 Mar 20.

4.

Inhibition of DNA Synthesis by a Platinum-Acridine Hybrid Agent Leads to Potent Cell Kill in Non-Small Cell Lung Cancer.

Smyre CL, Saluta G, Kute TE, Kucera GL, Bierbach U.

ACS Med Chem Lett. 2011 Aug 31;2(11):870-874.

5.

SOSTDC1 differentially modulates Smad and beta-catenin activation and is down-regulated in breast cancer.

Clausen KA, Blish KR, Birse CE, Triplette MA, Kute TE, Russell GB, D'Agostino RB Jr, Miller LD, Torti FM, Torti SV.

Breast Cancer Res Treat. 2011 Oct;129(3):737-46. doi: 10.1007/s10549-010-1261-9. Epub 2010 Nov 27.

6.

Ferroportin and iron regulation in breast cancer progression and prognosis.

Pinnix ZK, Miller LD, Wang W, D'Agostino R Jr, Kute T, Willingham MC, Hatcher H, Tesfay L, Sui G, Di X, Torti SV, Torti FM.

Sci Transl Med. 2010 Aug 4;2(43):43ra56. doi: 10.1126/scisignal.3001127. Erratum in: Sci Transl Med. 2010 Aug 25;2(46):46er1.

7.

The effects of low-frequency ultrasound (35 kHz) on methicillin-resistant Staphylococcus aureus (MRSA) in vitro.

Conner-Kerr T, Alston G, Stovall A, Vernon T, Winter D, Meixner J, Grant K, Kute T.

Ostomy Wound Manage. 2010 May;56(5):32-43.

8.

Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing.

Kute TE, Savage L, Stehle JR Jr, Kim-Shapiro JW, Blanks MJ, Wood J, Vaughn JP.

Cancer Immunol Immunother. 2009 Nov;58(11):1887-96. doi: 10.1007/s00262-009-0700-0. Epub 2009 Apr 2.

PMID:
19340424
9.

Measurement of PTEN expression using tissue microarrays to determine a race-specific prognostic marker in breast cancer.

Winter JL, Stackhouse BL, Russell GB, Kute TE.

Arch Pathol Lab Med. 2007 May;131(5):767-72.

PMID:
17488163
10.

Clarithromycin delays progression of bronchial epithelial cells from G1 phase to S phase and delays cell growth via extracellular signal-regulated protein kinase suppression.

Shinkai M, Tamaoki J, Kobayashi H, Kanoh S, Motoyoshi K, Kute T, Rubin BK.

Antimicrob Agents Chemother. 2006 May;50(5):1738-44.

11.

Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux.

Morrow CS, Peklak-Scott C, Bishwokarma B, Kute TE, Smitherman PK, Townsend AJ.

Mol Pharmacol. 2006 Apr;69(4):1499-505. Epub 2006 Jan 24.

PMID:
16434618
12.

Measurement of glut-1 expression using tissue microarrays to determine a race specific prognostic marker for breast cancer.

Stackhouse BL, Williams H, Berry P, Russell G, Thompson P, Winter JL, Kute T.

Breast Cancer Res Treat. 2005 Oct;93(3):247-53.

PMID:
16228617
13.

5-Oxo-ETE analogs and the proliferation of cancer cells.

O'Flaherty JT, Rogers LC, Paumi CM, Hantgan RR, Thomas LR, Clay CE, High K, Chen YQ, Willingham MC, Smitherman PK, Kute TE, Rao A, Cramer SD, Morrow CS.

Biochim Biophys Acta. 2005 Oct 1;1736(3):228-36. Epub 2005 Aug 30.

PMID:
16154383
14.

Tachpyridine, a metal chelator, induces G2 cell-cycle arrest, activates checkpoint kinases, and sensitizes cells to ionizing radiation.

Turner J, Koumenis C, Kute TE, Planalp RP, Brechbiel MW, Beardsley D, Cody B, Brown KD, Torti FM, Torti SV.

Blood. 2005 Nov 1;106(9):3191-9. Epub 2005 Jul 12.

15.

Polyploid formation via chromosome duplication induced by CTP:phosphocholine cytidylyltransferase deficiency and Bcl-2 overexpression: identification of two novel endogenous factors.

Shen YJ, DeLong CJ, Tercé F, Kute T, Willingham MC, Pettenati MJ, Cui Z.

J Histochem Cytochem. 2005 Jun;53(6):725-33.

PMID:
15928321
16.

19-Nor-1alpha,25-dihydroxyvitamin D2 (paricalcitol) exerts anticancer activity against HL-60 cells in vitro at clinically achievable concentrations.

Molnár I, Kute T, Willingham MC, Schwartz GG.

J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):539-43.

PMID:
15225834
17.

Prognostic markers in node-negative breast cancer: a prospective study.

Kute TE, Russell GB, Zbieranski N, Long R, Johnston S, Williams H, Stackhouse C, Wilkins L, Evans I, Berry P, Rimmer K, Tucker E.

Cytometry B Clin Cytom. 2004 May;59(1):24-31.

18.

Perillyl alcohol-mediated inhibition of lung cancer cell line proliferation: potential mechanisms for its chemotherapeutic effects.

Xu M, Floyd HS, Greth SM, Chang WC, Lohman K, Stoyanova R, Kucera GL, Kute TE, Willingham MC, Miller MS.

Toxicol Appl Pharmacol. 2004 Mar 1;195(2):232-46.

PMID:
14998688
19.

Development of Herceptin resistance in breast cancer cells.

Kute T, Lack CM, Willingham M, Bishwokama B, Williams H, Barrett K, Mitchell T, Vaughn JP.

Cytometry A. 2004 Feb;57(2):86-93.

20.
21.

Absence of HER2 overexpression in metastatic malignant melanoma.

Inman JL, Kute T, White W, Pettenati M, Levine EA.

J Surg Oncol. 2003 Oct;84(2):82-8.

PMID:
14502781
22.

Loss of expression of tropomyosin-1, a novel class II tumor suppressor that induces anoikis, in primary breast tumors.

Raval GN, Bharadwaj S, Levine EA, Willingham MC, Geary RL, Kute T, Prasad GL.

Oncogene. 2003 Sep 18;22(40):6194-203.

PMID:
13679858
23.

Intrabody-based strategies for inhibition of vascular endothelial growth factor receptor-2: effects on apoptosis, cell growth, and angiogenesis.

Wheeler YY, Kute TE, Willingham MC, Chen SY, Sane DC.

FASEB J. 2003 Sep;17(12):1733-5. Epub 2003 Jul 3.

PMID:
12958192
24.

19-nor-1alpha,25-dihydroxyvitamin D(2) (paricalcitol): effects on clonal proliferation, differentiation, and apoptosis in human leukemic cell lines.

Molnár I, Kute T, Willingham MC, Powell BL, Dodge WH, Schwartz GG.

J Cancer Res Clin Oncol. 2003 Jan;129(1):35-42. Epub 2003 Feb 12.

PMID:
12618899
25.

Genistein and vitamin D synergistically inhibit human prostatic epithelial cell growth.

Rao A, Woodruff RD, Wade WN, Kute TE, Cramer SD.

J Nutr. 2002 Oct;132(10):3191-4.

PMID:
12368417
26.

DNA strand breaks and cell cycle perturbation in herceptin treated breast cancer cell lines.

Mayfield S, Vaughn JP, Kute TE.

Breast Cancer Res Treat. 2001 Nov;70(2):123-9.

PMID:
11768602
27.

Expression of microtubule-associated protein 2 in benign and malignant melanocytes: implications for differentiation and progression of cutaneous melanoma.

Fang D, Hallman J, Sangha N, Kute TE, Hammarback JA, White WL, Setaluri V.

Am J Pathol. 2001 Jun;158(6):2107-15.

28.
29.

Influence of coenzyme A-independent transacylase and cyclooxygenase inhibitors on the proliferation of breast cancer cells.

Trimboli AJ, Waite BM, Atsumi G, Fonteh AN, Namen AM, Clay CE, Kute TE, High KP, Willingham MC, Chilton FH.

Cancer Res. 1999 Dec 15;59(24):6171-7.

30.

Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells.

Clay CE, Namen AM, Atsumi G, Willingham MC, High KP, Kute TE, Trimboli AJ, Fonteh AN, Dawson PA, Chilton FH.

Carcinogenesis. 1999 Oct;20(10):1905-11.

PMID:
10506103
31.

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.

Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, Barcos M, Cirrincione C, Edgerton S, Allred C, Norton L, Liu ET.

J Natl Cancer Inst. 1998 Sep 16;90(18):1346-60.

PMID:
9747866
32.

Relationship of nm23 to proteolytic factors, proliferation and motility in breast cancer tissues and cell lines.

Russell RL, Pedersen AN, Kantor J, Geisinger K, Long R, Zbieranski N, Townsend A, Shelton B, Brünner N, Kute TE.

Br J Cancer. 1998 Sep;78(6):710-7.

33.

Oligosaccharide sequence of human breast cancer cell heparan sulfate with high affinity for laminin.

Parthasarathy N, Gotow LF, Bottoms JD, Kute TE, Wagner WD, Mulloy B.

J Biol Chem. 1998 Aug 14;273(33):21111-4.

34.

Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence.

Kute TE, Grøndahl-Hansen J, Shao SM, Long R, Russell G, Brünner N.

Breast Cancer Res Treat. 1998 Jan;47(1):9-16.

PMID:
9493971
35.

Human chondrocyte expression of growth-arrest-specific gene 6 and the tyrosine kinase receptor axl: potential role in autocrine signaling in cartilage.

Loeser RF, Varnum BC, Carlson CS, Goldring MB, Liu ET, Sadiev S, Kute TE, Wallin R.

Arthritis Rheum. 1997 Aug;40(8):1455-65.

PMID:
9259426
36.

Flow cytometric analysis of lymph node metastases in advanced ovarian cancer: clinical and biologic significance.

Kimball RE, Schlaerth JB, Kute TE, Schlaerth AC, Santoso J, Ballon SC, Spirtos NM.

Am J Obstet Gynecol. 1997 Jun;176(6):1319-26; discussion 1326-7.

PMID:
9215191
37.

nm23--relationship to the metastatic potential of breast carcinoma cell lines, primary human xenografts, and lymph node negative breast carcinoma patients.

Russell RL, Geisinger KR, Mehta RR, White WL, Shelton B, Kute TE.

Cancer. 1997 Mar 15;79(6):1158-65.

PMID:
9070493
38.

Elevated expression of retinoic acid receptor-alpha (RAR alpha) in estrogen-receptor-positive breast carcinomas as detected by immunohistochemistry.

Han QX, Allegretto EA, Shao ZM, Kute TE, Ordonez J, Aisner SC, Rishi AK, Fontana JA.

Diagn Mol Pathol. 1997 Feb;6(1):42-8.

PMID:
9028736
39.

Potent antitumour activity of a new class of tumour-specific killer cells.

Chen SY, Yang AG, Chen JD, Kute T, King CR, Collier J, Cong Y, Yao C, Huang XF.

Nature. 1997 Jan 2;385(6611):78-80.

PMID:
8985250
40.

Analysis of cathepsin D from breast tissues by capillary electrophoresis.

Shihabi ZK, Kute TE.

J Chromatogr B Biomed Appl. 1996 Aug 9;683(1):125-31.

PMID:
8876448
41.

Flow cytometry in node-positive breast cancer: cancer and leukemia group B protocol 8869.

Kute TE, Quadri Y, Muss H, Zbieranski N, Cirrincione C, Berry DA, Barcos M, Thor AP, Liu E, Koerner F, et al.

Cytometry. 1995 Dec 15;22(4):297-306.

42.

Membrane-interactive phospholipids inhibit HIV type 1-induced cell fusion and surface gp160/gp120 binding to monoclonal antibody.

Krugner-Higby L, Goff D, Edwards T, Iyer N, Neufeld J, Kute T, Morris-Natschke S, Ishaq K, Piantadosi C, Kucera LS.

AIDS Res Hum Retroviruses. 1995 Jun;11(6):705-12.

PMID:
7576930
43.

Synchronization of cells in the S phase of the cell cycle by 3'-azido-3'-deoxythymidine: implications for cell cytotoxicity.

Chandrasekaran B, Kute TE, Duch DS.

Cancer Chemother Pharmacol. 1995;35(6):489-95.

PMID:
7882457
44.

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.

Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, et al.

N Engl J Med. 1994 May 5;330(18):1260-6. Erratum in: N Engl J Med 1994 Jul 21;331(3):211.

45.

Expression of the retinoic Acid nuclear receptors (rars) and retinoid x-receptor (rxr) genes in estrogen-receptor positive and negative breast-cancer.

Shao Z, Sheikh M, Chen J, Kute T, Aisner S, Schnaper L, Fontana J.

Int J Oncol. 1994 Apr;4(4):859-63.

PMID:
21566993
46.

DNA Cytometry Consensus Conference. Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast.

Hedley DW, Clark GM, Cornelisse CJ, Killander D, Kute T, Merkel D.

Breast Cancer Res Treat. 1993 Oct;28(1):55-9. Review.

PMID:
8123870
47.

Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast. Report of the DNA Cytometry Consensus Conference.

Hedley DW, Clark GM, Cornelisse CJ, Killander D, Kute T, Merkel D.

Cytometry. 1993;14(5):482-5. Review. No abstract available.

48.

Cathepsin D as a prognostic indicator for node-negative breast cancer patients using both immunoassays and enzymatic assays.

Kute TE, Shao ZM, Sugg NK, Long RT, Russell GB, Case LD.

Cancer Res. 1992 Oct 1;52(19):5198-203.

49.

IGFBP-3 gene expression and estrogen receptor status in human breast carcinoma.

Shao ZM, Sheikh MS, Ordonez JV, Feng P, Kute T, Chen JC, Aisner S, Schnaper L, LeRoith D, Roberts CT Jr, et al.

Cancer Res. 1992 Sep 15;52(18):5100-3.

50.

Deoxypyrimidine-induced inhibition of the cytokinetic effects of 1-beta-D-arabinofuranosyluracil.

Chandrasekaran B, Kute TE, Capizzi RL.

Cancer Chemother Pharmacol. 1992;29(6):455-60.

PMID:
1568288

Supplemental Content

Support Center